Metabolic basis for the persistence of dormant Toxoplasma gondii infection
Project Number5R01AI172811-03
Contact PI/Project LeaderBZIK, DAVID J
Awardee OrganizationDARTMOUTH COLLEGE
Description
Abstract Text
Dormant Toxoplasma gondii [Toxoplasma] infection is characterized by dormant bradyzoite stage parasites
that reside within thick-walled cysts that develop inside neurons in the central nervous system. Cysts provide
a structural and physiological habitat that sustains the viability of dormant bradyzoite stage parasites. While
many targets and therapeutics have been identified to effectively treat the active Toxoplasma infection that is
defined by rapidly replicating tachyzoite stage parasites, therapeutic strategies or drugs that eliminate
dormant bradyzoites and their cysts have not been identified. The identification of potential targets to perturb
or eliminate dormancy has proven challenging for many microbes, including Toxoplasma, because microbial
dormancy is characterized by a reduced metabolic state that sustains viability but not replication. Several
lines of evidence support the hypothesis that dormant bradyzoites have markedly reduced mitochondrial
functions and rely more heavily on acquiring host glucose not just for energy production but also to meet an
increased demand for glucose to build bradyzoite-stage amylopectin and cyst wall glycan biomass. Consistent
with this hypothesis, our data has shown that blocking the utilization of host glucose markedly reduced the
development as well as the persistence of dormant stage bradyzoites. Here, we propose to define the
metabolic basis that underpins the ability of glucose starvation to prevent the development and persistence
of dormant bradyzoites. Targeting mitochondrial functions such as the electron transport chain has been
shown to have a partial ability to perturb but not to eliminate dormancy. We hypothesize that targeting glucose
or glucose + lactate utilization in combination with inhibition of mitochondrial function will accelerate the
demise of dormant bradyzoites and their cysts. The work in this proposal charts a way forward to identify a
metabolic basis to eliminate Toxoplasma dormancy.
Public Health Relevance Statement
Currently, there is no drug or strategy that targets or eliminates dormant Toxoplasma gondii infection. This
project will identify and validate a metabolic basis to eliminate the dormant stage of Toxoplasma gondii
infection. The results obtained in this work will advance mechanistic understanding of dormancy, and will
illuminate and test new strategies that can eliminate the dormant stage of infection.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
041027822
UEI
EB8ASJBCFER9
Project Start Date
23-November-2022
Project End Date
31-October-2027
Budget Start Date
01-November-2024
Budget End Date
31-October-2025
Project Funding Information for 2025
Total Funding
$397,700
Direct Costs
$242,500
Indirect Costs
$155,200
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$397,700
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI172811-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI172811-03
Patents
No Patents information available for 5R01AI172811-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI172811-03
Clinical Studies
No Clinical Studies information available for 5R01AI172811-03
News and More
Related News Releases
No news release information available for 5R01AI172811-03
History
No Historical information available for 5R01AI172811-03
Similar Projects
No Similar Projects information available for 5R01AI172811-03